This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech May Be Ready to Get Off the Floor

For the biotech sector, it feels like late September.

Battered biotech stocks are revisiting the lows last seen in the weeks after the terrorist attacks in New York and Washington, D.C. And like those pessimistic times, there are few biotech traders on Wall Street willing to step up and buy.

But on a brighter note, there were good signals Friday that the sector might be hitting a bottom, observers say. So when do biotech stocks start rising in a significant way? Unfortunately, that's a question few are brave enough to answer.

"When it's raining outside for as long as it has, it's hard to think about seeing the sun tomorrow," says Jon Alsenas, fund manager at ING Furman Selz Asset Management, summing up the doldrums gripping normally buoyant biotech investors these days.

Real numbers bear witness to the troubles. The bellwether Amex Biotechnology Index slumped Friday to an intraday low of 423.44, a level not seen since the opening of trading post-Sept. 11. A small recovery was staged at midday, but it petered out at the end of the day. The index closed Friday at 428.94, which dropped it 11% for the week and 25% for the year.

Friday is certainly a day diehard biotech investors want to forget, but a recap of the carnage is instructive to understand what might lie ahead. The day actually opened with some optimism because Amgen (AMGN), on Thursday night, capped off what was a mediocre biotech earnings season with a relatively strong report, including a bullish boost in guidance for sales growth.

But whatever good mojo the No. 1 biotech firm sprinkled on the sector early vanished fast as rumors spread that one or more big biotech funds were being hit with redemptions, forcing the funds to liquidate large positions. No one seemed able to pinpoint exactly who was in trouble, but it didn't really matter, as fund managers all over Wall Street began selling.

One Thing Leads to Another

That led to across-the-board losses Friday: Amgen, despite good news, fell 2.5%; Genentech (DNA) fell 4%; Cephalon (CEPH) dropped 5%; Gilead Sciences (GILD) lost 9%; Idec Pharmaceuticals (IDPH) was off 4%; and Genta (GNTA) dropped 9%.

But the selloff may have also signaled capitulation.

"When you start hearing rumors about this fund or that fund going out of business, it usually signals that we're at a bottom," says Robertson Stephens senior biotech analyst Mike King. "I think we test the 400 levels [of the Amex Biotech Index], but we should hold."

Stabilizing the sector is one thing, but getting it to move up in a meaningful way still requires courage not in abundance these days.

Biotech Hits the Floor
A test of post-Sept. 11 lows is in the offing
Source: Yahoo! Finance

"There is just no conviction in the market right now," says one biotech hedge fund manager. "I certainly don't want to be the first one in so I can get run over."

Another fund manager, exasperated by indiscriminate selling, even pines for the good old days when sell-side analysts led cheers for stocks -- and investors listened.

"Some of the selling [Friday] morning was crazy, but as we reached Sept. 11 lows, I didn't get one phone call, or one email, from any analysts supporting the sector," he says. "Analysts are so skittish these days that they're scared to say anything. The machine is broken."

The problem, of course, is that many of the marquee biotech stocks still aren't cheap. Genentech stock has fallen about 20% this year, but the company still trades at 40 times 2002 earnings. Idec Pharmaceuticals is one of the fastest-growing companies in the sector, but how excited can investors get when the stock -- down 17% for the year -- trades at 61 times 2002 earnings or 45 times 2003 earnings?

In fact, the only profitable biotech company that looks somewhat attractive these days is Biogen (BGEN), which trades at a relatively cheap 20 times 2003 earnings. But Biogen is loaded with risks. The bull story gets really ugly if its psoriasis drug, Amevive, doesn't get approved later this year.

But this negativity won't last forever. Fund manager Alsenas says investors have to pick themselves up off the floor and get back in the game like they did post Sept. 11. That means looking for stocks with good growth stories that have been trampled, unfairly in today's bear market.

"Six months from now, I don't want to be kicking myself for not owning these stocks," he says.

Alsenas says he's buying CV Therapeutics (CVTX) because its heart drug, Ranolazine, will be a winner, despite a lot of naysayers who believe otherwise. He also likes Scios (SCIO) -- yes, it has a lofty valuation -- but its heart drug, Natrecor, should continue to surprise Wall Street with better-than-expected growth.

This is a start, but the biotech sector needs more good news, and more buyers, before it gets its shine back.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
SCIO $0.27 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs